scispace - formally typeset
I

Ivan Topisirovic

Researcher at McGill University

Publications -  146
Citations -  16418

Ivan Topisirovic is an academic researcher from McGill University. The author has contributed to research in topics: EIF4E & Translation (biology). The author has an hindex of 53, co-authored 137 publications receiving 13889 citations. Previous affiliations of Ivan Topisirovic include Jewish General Hospital & Samsung Medical Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

TL;DR: Control of cell size and cell cycle progression appear to be independent in mammalian cells, whereas in lower eukaryotes, 4E-BPs influence both cell growth and proliferation.
Journal ArticleDOI

Targeting the translation machinery in cancer

TL;DR: The role of translation in cancer is discussed, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and an overview of recent efforts aiming to 'translate' these results to the clinic is provided.
Journal ArticleDOI

mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation

TL;DR: It is demonstrated that mTORC1 controls mitochondrial activity and biogenesis by selectively promoting translation of nucleus-encoded mitochondria-related mRNAs via inhibition of the eukaryotic translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs).
Journal ArticleDOI

Dissecting the role of mTOR: lessons from mTOR inhibitors.

TL;DR: The molecular underpinnings of the action of rapamycin and novel active-site mTOR inhibitors are reviewed as well as potential advantages and caveats associated with the use of these drugs in the treatment of cancer.